Author

G. Arpino

h-index 45 View on Semantic Scholar

We have 3 of 313 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Optimizing early identification and management of trastuzumab deruxtecan-related interstitial lung disease: insights from a multidisciplinary expert panel

Proactive surveillance strategies are essential to minimize ILD-related morbidity while preserving access to T-DXd therapy and the implementation of standardized clinical pathways and the development of biomarker-driven approaches may further improve personalized ILD risk management.

L. Licata, C. Lisanti, G. Arpino et al. · Frontiers in Oncology · 0 citations

Open access Sep 2026

Prognostic value of hormone receptor expression in patients with HR+/HER2− advanced BC treated with first-line ET+CDK4/6i: results from the multicentre observational, real-world PALMARES-2 study

Effectiveness of first-line ET plus CDK4/6i in patients with HR+/HER2− aBC worsens progressively with decreasing ERα expression, and PgR expression adds further prognostic discrimination, with low ERα and PgR expression identifying a subgroup of patients with particularly poor outcomes.

F. Ligorio, L. Provenzano, R. Caputo et al. · EClinicalMedicine · 0 citations

Review Open access Jul 2026

Unraveling the use of vaccine therapy in HER-2 positive breast cancer: a comprehensive review of current state and future perspectives

While advanced-stage BC often presents an immunosuppressive tumor microenvironment that hinders vaccine efficacy, early-stage disease offers a more favorable immunological milieu for inducing robust and durable T-cell responses.

A. Caltavituro, C. Martinelli, M. Palleschi et al. · Journal of Experimental &amp... · 0 citations